Prevention of HIV/AIDS

PHASE 1 TEST RESULTS FOR A NOVEL HIV PREVENTION GEL PRESENTED AT THE HIVR4P MEETING

Retrieved on: 
Thursday, January 28, 2021
Microbicides, Prevention of HIV/AIDS, Sexually transmitted diseases and infections, Medical specialties, HIV/AIDS, Pandemics, Microbiology, Branches of biology, Rectal microbicide, Microbicides for sexually transmitted diseases

The OB-002H-101 Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of the OB-002H gel which is being developed for a HIV prevention indication.

Key Points: 
  • The OB-002H-101 Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of the OB-002H gel which is being developed for a HIV prevention indication.
  • Stage 1 was an open-label single-dose vaginal or rectal application of the OB-002H gel in 12 participants.
  • Dr. Ian McGowan, Chief Medical Officer at Orion Biotechnology stated, We are delighted to have the opportunity to present our Phase 1 data for the OB-002H gel at the HIVR4P meeting.
  • There remains a significant unmet need for HIV prevention products that women and men can use to protect themselves from HIV infection.

Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021

Retrieved on: 
Tuesday, January 26, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medicine, Pre-exposure prophylaxis, Prevention of HIV/AIDS, Health sciences, HIV Prevention Trials Network

In the interim analysis using blinded data, both monthly doses of islatravir were found to have an acceptable tolerability profile.

Key Points: 
  • In the interim analysis using blinded data, both monthly doses of islatravir were found to have an acceptable tolerability profile.
  • These data are shared as a late-breaking oral presentation during the virtual 2021 HIV Research for Prevention Conference (HIVR4P 2021) and featured in the official press conference of HIVR4P 2021.
  • There is an urgent need for additional, longer acting HIV prevention options to help a wider range of people protect themselves.
  • Our data at HIVR4P support evaluating islatravir as a once-monthly oral PrEP option in the phase 3 IMPOWER trials, which will enroll across diverse populations and geographies.

The Beginning of the End for HIV

Retrieved on: 
Tuesday, January 26, 2021
Medicine, Clinical medicine, HIV/AIDS, Health, Pandemics, Pre-exposure prophylaxis, HIV, Prevention of HIV/AIDS, Epidemiology of HIV/AIDS, Draft:Ending the HIV Epidemic Initiative

New reports indicated HIV had originated in Haiti, and it continued to spread like wildfires in Europe and Uganda.

Key Points: 
  • New reports indicated HIV had originated in Haiti, and it continued to spread like wildfires in Europe and Uganda.
  • PrEP (pre-exposure prophylaxis) is an HIV prevention prescription for people who don't have HIV that helps reduce their risk of getting HIV if exposed to the virus.
  • Testing and treatments, like PrEP, have shown significant progress in the fight to end the HIV epidemic.
  • "We can accomplish the end of HIV in Houston and across the nation by 2030 if we work together."

Global Antiretroviral Therapy Market Outlook to 2024, Featuring Company Profiles of Key Players Gilead Sciences, GSK, Roche Holding, Boehringer Ingelheim, Cipla and Abbvie

Retrieved on: 
Thursday, January 21, 2021
Hepatotoxins, Drugs, Prevention of HIV/AIDS, Integrase inhibitors, Management of HIV/AIDS, Protease inhibitor, Reverse-transcriptase inhibitor, Cipla, Health care, Boehringer Ingelheim, Zidovudine, Health

The global antiretroviral therapy market is anticipated to reach US$ 35.14 billion in 2024.

Key Points: 
  • The global antiretroviral therapy market is anticipated to reach US$ 35.14 billion in 2024.
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and the huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The competitive landscape of the market, along with the company profiles of leading players (Gilead Sciences, GSK, Roche Holding, Boehringer Ingelheim, Cipla and Abbvie) are also presented in detail.

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Retrieved on: 
Monday, December 21, 2020
AIDS, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Non-nucleoside reverse transcriptase inhibitors, Integrase inhibitors, Prevention of HIV/AIDS, Organic compounds, Medicine, Nitriles, Pyrimidines, Rilpivirine, HIV/AIDS, Cabotegravir, ViiV Healthcare

This authorisation represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets, following the oral initiation phase.

Key Points: 
  • This authorisation represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets, following the oral initiation phase.
  • Cabotegravir is an INI developed by ViiV Healthcare for the treatment of HIV-1 in virologically suppressed adults.
  • Cabotegravir and rilpivirine injections are administered as two IM injections in the buttocks by a Healthcare Professional at the same appointment.
  • Physicians should refer to current treatment guidelines for the management of HIV infection in patients co-infected with hepatitis B virus.

MISTR, the nation's leading telemedicine platform for PrEP, now available in Spanish

Retrieved on: 
Wednesday, December 9, 2020
Articles, Prevention of HIV/AIDS, Assistive technology, Telehealth, Pre-exposure prophylaxis, Prep, Latinx, Technology, Science and technology

Recognizing this, MISTR has made its' telemedicine (telePrEP) platform available in Spanish to better serve the Latinx community.

Key Points: 
  • Recognizing this, MISTR has made its' telemedicine (telePrEP) platform available in Spanish to better serve the Latinx community.
  • With mistr.com now available in Spanish and supported by Spanish speaking medical providers and customer support team, MISTR hopes to eliminate any further hesitation from those within the Latinx community seeking PrEP.
  • Having MISTR available in Spanish will help us change the disproportionate impact of HIV on the Spanish speaking Latinx population in Texas."
  • MISTR is a telemedicine (telePrEP) platform offering easy online access to pre-exposure prophylaxis (PrEP) across the United States.

Looking For A New Girlfriend In 2021? Resolve To Have Better Hygiene, According To Recent Survey

Retrieved on: 
Tuesday, December 1, 2020
Sexual health, Condom, HIV/AIDS, Penis, Prevention of HIV/AIDS, Medical specialties, Health, Clinical medicine

Of the 500+ women surveyed, here are the biggest offenders:

Key Points: 
  • Of the 500+ women surveyed, here are the biggest offenders:
    "Proximity, money and family dynamics can't hold a candle to the basics," said Neil Mehta, M.P.H., founder and CEO of Royal.
  • "I've always said healthy is sexy, but seeing these numbers really reinforces that sentiment."
  • Also of note, 93 percent of women are more attracted to a partner who offers to use a condom rather than waiting until they ask for one.
  • Royal is the provider of all-natural, high quality, non-toxic sexual wellness and personal care products.

BlueCity pledges donation towards HIV prevention ahead of World AIDS Day, following brand’s pioneering work in the field

Retrieved on: 
Tuesday, November 24, 2020
BlueCity, Recycling, Rotterdam, Prevention of HIV/AIDS, HIV/AIDS activism

The funds will be used to support the HIV prevention work of prospective non-profit organizations in their community outreach and capacity building.

Key Points: 
  • The funds will be used to support the HIV prevention work of prospective non-profit organizations in their community outreach and capacity building.
  • The brand will also actively seek applications and provide grants for programs focusing on HIV prevention among young people, according to Baoli Ma, founder, chairman and chief executive officer of BlueCity.
  • Since the founding of Danlan Public Interest in 2008, BlueCity has pioneered the concept of Internet + HIV prevention in China, which essentially integrates online and offline HIV prevention efforts.
  • Partnered with CFPSA, BlueCity also established and provided the initial funding used by Danlan Public Interest Fund in August 2019 to strengthen HIV prevention efforts among Chinas youth.

Viatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR

Retrieved on: 
Monday, November 23, 2020
Hepatotoxins, Integrase inhibitors, Prevention of HIV/AIDS, Dolutegravir, Organofluorides, Management of HIV/AIDS, Medical specialties, Health care, Health

Pediatric dolutegravir tablets were approved for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in pediatric patients at least 4 weeks old and weighing at least 3 kg.

Key Points: 
  • Pediatric dolutegravir tablets were approved for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in pediatric patients at least 4 weeks old and weighing at least 3 kg.
  • The World Health Organization (WHO) recommends this product as part of a preferred first-line treatment regimen for children who meet the criteria.
  • Pediatric dolutegravir tablets are a significant new addition to a product portfolio that has made Viatris the world's largest supplier of ARVs.
  • Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.

Having a Baby Boy? Intact America Warns, 'Get Ready for the Circumcision Sellers!'

Retrieved on: 
Wednesday, November 18, 2020
Circumcision, Articles, Men's rights, Medical specialties, Men's Health, Prevention of HIV/AIDS, Cosmetic surgery, Clinical medicine, Intact America, Reproductive health, Circumcision and law, Religious male circumcision

The Intact America 2020 survey is the first time researchers have shown the direct correlation between solicitation and an increased circumcision rate.

Key Points: 
  • The Intact America 2020 survey is the first time researchers have shown the direct correlation between solicitation and an increased circumcision rate.
  • Only 45% of new mothers circumcised their sons without being asked, compared to 78% of new mothers who had been solicited.
  • Even a "soft sell," such as giving the mother a consent form to perform the procedure, increased circumcisions by 137%.
  • Intact America is the largest national advocacy group working to end involuntary child genital cutting in America and to ensure healthy sexual futures for all people.